Overexpression of CRM1 is found in HNC [25,32], prostate cancer [13], breast cancer [14], cervical cancer [15], glioma [16], osteosarcoma [17], ovarian cancer [18], esophageal cancer [35], Kaposi’s sarcoma [36], pancreatic cancer [37], lung cancer [38], gastric cancer [39], renal cell carcinoma [39], hepatocellular carcinoma [41], acute myeloid/lymphoid leukemia [42], and chronic lymphoid leukemia [43], and this level of increase has been reported to be associated with metastasis, histological grade, increased tumor size, and lower overall survival. This evidence concerns the gene XPO1 and renal cell carcinoma.